Bill Gates-backed Ginkgo Bioworks going public via $15 billion SPAC

Ginkgo Bioworks is going public via a merger with former MGM CEO Harry Sloan's SPAC in a deal that values the biotech company at $15 billion.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.